Biotech Planet


Curtis Hodge, Ph.D.

Curtis Hodge, Ph.D.

Co-Founder & CEO of Nanotein Technologies.

Curtis Hodge is the CEO and Co-Founder of Nanotein Technologies, Inc., a biotech startup company in the San Francisco Bay Area that has developed a reagent for superior T cell therapy manufacturing, addressing several current limitations and helping customers to make more effective cell therapies, faster. He received his PhD in Biochemistry from the University of Alberta in Canada, where he characterized the biophysics, biochemistry, and cellular phenotypes of native and engineered proteins/enzymes involved in DNA repair and ubiquitination. He gained cancer immunology training as a postdoc at UC Berkeley, then developed Nanotein’s protein-based platform technology during a postdoc at Lawrence Berkeley National Lab. His education and training were funded through several awards, including competitive national awards, notably the Alexander Graham Bell Canada Graduate Scholarship and Canadian Institutes of Health Research Postdoctoral Fellowship. Through his leadership, Nanotein Technologies was chosen as a Top Emerging Biotech by QB3, a UC Berkeley-UCSF incubator, as a 2019 cohort of Biotech/Biopharma for their innovative technologies and potential market impact. Additionally, Nanotein has raised a substantial seed round, and established a strategic partnership with a pharmaceutical company for development of their innovative technology.


Back to Top